Biotech Updates: Acrivon CLIA Lab, Lilly M&A Spree, Defence Radiopharma COO
Acrivon launched a CLIA-certified lab. Eli Lilly disclosed over 5 trillion won in M&A and licensing. Defence Therapeutics named a new radiopharmaceutical COO.
Novo Nordisk A/S
CompanyAlso known as: Novo, Novo Nordisk
Company Profile
Novo Nordisk is a global healthcare company focused on defeating serious chronic diseases, especially diabetes and obesity. The company is active in more than 80 countries and markets products in about 170 countries worldwide.
- Website
- https://www.novonordisk.com
- Headquarters
- Bagsvaerd, Denmark
- Founded
- 1923
- Stock Ticker
- NYSE:NVO
Related News
Novo Nordisk and AWS Launch Strategic AI Partnership to Accelerate Drug Discovery
Novo Nordisk and AWS announced a strategic AI partnership for drug discovery, including a London co-innovation hub. AWS is now the preferred cloud provider, with productivity gains for 25,000 employees.
UK Regulator Reports 150,000 Adverse Events and 153 Deaths Linked to Weight-Loss Jabs
UK data links 150+ deaths to weight-loss jabs. A new study finds a vegan diet led to 5.9kg average loss in 4 months vs 6.9kg over 9 months for semaglutide.
Lupin Posts Record Q3 FY2026 Results, Prepares Generic Semaglutide Launch
Lupin reported record Q3 FY2026 revenue of INR 7,168 crores and a 31.1% EBITDA margin, while preparing to launch a generic semaglutide and shifting focus to innovation. The company also secured US FDA approval for Pegfilgrastim and EU approval for ranibizumab biosimilar.
Biotech Funding News: Novo Nordisk Programme, CIRM Grant, and Company Financings
Biotech funding roundup: $8M CIRM grant to Siren, $3.5M pre-seed for Claryx, Syntax Bio's $14.4M Series A, €80M Novo Nordisk Foundation programme, and Appili's NIAID contract termination.
Patent Cliff: Blockbuster Drugs Worth Up to $500B Face Generic Competition
Blockbuster drugs worth hundreds of billions face generic competition as patents expire through 2032. Indian drugmakers could capture $3-5 billion of the opportunity, while GSK and Bristol Myers Squibb prepare for revenue losses.
GLP-1 Boom: One in Eight U.S. Adults Now Taking Drugs, Driving Manufacturing and Consumer Shifts
One in eight U.S. adults now takes a GLP-1, and prescriptions among non-diabetics rose 700% since 2019. The market is projected to reach $200 billion by 2030, driving manufacturing investments and consumer food shifts.
GLP-1 Drugs: Smell and Taste Risks, Soaring Poison Calls, and Reshaped Food Demand
GLP-1 receptor agonists are linked to a higher risk of smell and taste disturbances, while poison control calls involving semaglutide have soared since 2021. The drugs produce significant weight loss and are reshaping U.S. food demand, with roughly one in eight adults now taking them.
Lilly Amasses $1.5B Stockpile for Oral Obesity Drug as Logistics and Amylin Sectors Surge
Eli Lilly builds $1.5B stockpile for oral obesity drug orforglipron; study shows GLP-1s cut cancer risk; logistics firms invest in cold chain; and amylin drug race heats up with $19B in deals.
UK Approves First GLP-1 Weight Loss Tablet as Semaglutide Landscape Shifts
The UK MHRA approved oral semaglutide (Wegovy) as the first GLP-1 weight loss tablet on 11 June 2026. A new report links high-dose tirzepatide to anhedonia, and data show bariatric surgery declining sharply as GLP-1 use surges.
Related Clinical Trials
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT07770841 |
Research Study on How Well Oral Semaglutide Works for Weight Loss in Adults With Excess Body Weight |
RECRUITING | PHASE3 |
| NCT07769489 |
Study to Assess Tolerability of Injecting Larger Volumes (2-5 mL) Subcutaneously at Different Rates: Participant Experience and Acceptance |
NOT_YET_RECRUITING | PHASE1 |
| NCT07767175 |
A First-in-human Research Study on How NNC0721-8060 Works in People Living With Overweight or Obesity |
NOT_YET_RECRUITING | PHASE1 |
| NCT07757087 |
A Research Study to See How NNC0487-0111 Affects the Body's Energy Use After a Weight Loss in Adults Living With Obesity, Compared to a Low-calorie Diet or Placebo |
RECRUITING | PHASE1 |
| NCT07745504 |
A Research Study to Compare Two Different Versions of Injectable Cagrilintide and Placebo in People With Excess Body Weight |
NOT_YET_RECRUITING | PHASE3 |
| NCT07739901 |
Korean Real-world Study on MASLD/MASH Outcomes. |
ACTIVE_NOT_RECRUITING | |
| NCT07731256 |
Semaglutide for Low Back Pain |
NOT_YET_RECRUITING | PHASE2 |
| NCT07720271 |
AMAZE 9: A Research Study Investigating How Well Zenagamtide Tablets Help People With Excess Body Weight Lose Weight |
NOT_YET_RECRUITING | PHASE3 |
| NCT07713901 |
Database Linkage Study to Evaluate the Risk of Medullary Thyroid Carcinoma |
ENROLLING_BY_INVITATION | |
| NCT07710768 |
A Research Study on How UBT251 Affects Levels of Midazolam, Caffeine and Warfarin in the Blood of Participants With Excess Body Weight |
RECRUITING | PHASE1 |